CRISPR Therapeutics AG’s recently made public that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $3.46 million on Oct 17 ’25. In the deal valued at $67.91 per share,50,895 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 254,201 shares worth roughly $16.71 million.
Then, Kulkarni Samarth sold 4,242 shares, generating $282,517 in total proceeds. Upon selling the shares at $66.60, the Chief Executive Officer now owns 205,096 shares.
Before that, KASINGER JAMES R. sold 1,076 shares. CRISPR Therapeutics AG shares valued at $71,662 were divested by the General Counsel and Secretary at a price of $66.60 per share. As a result of the transaction, KASINGER JAMES R. now holds 83,402 shares, worth roughly $5.48 million.
JP Morgan initiated its CRISPR Therapeutics AG [CRSP] rating to an Overweight in a research note published on September 18, 2025; the price target was $70. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in mid February from “an In-line” to “an Outperform”. TD Cowen also remained covering CRSP and has increased its forecast on February 12, 2025 with a “Hold” recommendation from previously “Sell” rating. H.C. Wainwright started covering the stock on February 03, 2025. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -2.80% to $65.72. Over the last five days, the stock has lost -11.15%. CRISPR Therapeutics AG shares have risen nearly 42.87% since the year began. Nevertheless, the stocks have risen 66.97% over the past one year. While a 52-week high of $78.48 was reached on 10/08/25, a 52-week low of $30.04 was recorded on 04/07/25.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 63.97, which if violated will result in even more drops to 62.22. On the upside, there is a resistance level at 67.60. A further resistance level may holdings at 69.48.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-10-15, dropping by -2.76 million shares to a total of 21.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 23.81 million shares. There was a decline of -13.13%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 06, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $84.
